**Supplementary Table 1. Odds ratio for being INR20% 36 months after initiating ART.**

|  |  |  |
| --- | --- | --- |
| **Variable**  | **OR (99%CI)** | ***p* value** |
| Age (1 year older)  | 1.01 (0.98-1.03) | 0.754 |
| Male sex | 1.45 (0.66-3.17) | 0.352 |
| Non-Italian nationality | 0.66 (0.29-1.49) | 0.660 |
| Risk factor for HIV (Ref. Heterosexuals) |  |  |
| - MSM  | 1.56 (0.77-3.16) | 0.214 |
| - IVDU  | 0.89 (0.25-3.20) | 0.858 |
| - Unknown  | 1.8e-7-8 (0-inf) | 0.987 |
| CDC stage C | 0.26 (0.08-0.09) | 0.027 |
| HCV-RNA positivity  | 0.72 (0.21-2.48) | 0.602 |
| HBsAg positivity  | 1.78 (0.48-6.61) | 0.387 |
| CMV IgG positivity | 1.89 (0.43-8.33) | 0.401 |
| Chemotherapy | 4.2e-7 (0-inf) | 0.986 |
| Death | 4.3e-7 (0-inf) | 0.989 |
| **Immunovirological data** |  |  |
| CD4 nadir  | 1.003 (1.001-1.004) | <0.001 |
| CD4/CD8 ratio at baseline | 7.99 (3.24-19.70) | <0.001 |
| CD8 at 36 months  | 0.99 (0.99-1.00) | 0.006 |
| HIV-RNA zenith (for each log10 copies/mL) | 0.74 (0.55-0.99) | 0.039 |
| Months to HIV-RNA ≤ 50 copies/mL  | 0.94 (0.84-1.05) | 0.273 |
| **Therapy**  |  |  |
| Months of INI exposure | 1.01 (0.98-1.02) | 0.727 |
| Months of PI exposure | 0.99 (0.96-1.01) | 0.987 |
| Months of NNRTI exposure | 1.01 (0.99-1.03) | 0.157 |

SD, standard deviation; MSM, men who have sex with men; IVDU intravenous drug users; HBsAg epatitis B surface antigen; IQR, interquartile range.

**Supplementary Table 2. Odds ratio for being INR500 36 months after initiating ART. Only people with CD4 nadir below 500 cells/mmc included in the analysis (N=280).**

|  |  |  |
| --- | --- | --- |
| **Variable**  | **OR (99%CI)** | ***p* value** |
| Age (1 year older)  | 1.01 (0.99-1.03) | 0.465 |
| Male sex | 1.44 (0.83-2.50) | 0.191 |
| Non-Italian nationality | 1.88 (1.10-3.22) | 0.021 |
| Risk factor for HIV (Ref. Heterosexuals) |  |  |
| - MSM  | 0.99 (0.57-1.27) | 0.984 |
| - IVDU  | 1.23 (0.54-2.80) | 0.619 |
| - Unknown  | 0.96 (0.30-3.07) | 0.948 |
| CDC stage C | 2.93 (1.67- 5.12) | <0.001 |
| HCV-RNA positivity  | 1.34 (0.61-2.93) | 0.465 |
| HBsAg positivity  | 1.53 (0.52-4.50) | 0.436 |
| CMV IgG positivity | 0.84 (0.35-2.02) | 0.692 |
| Chemotherapy | 2.57 (0.60-10.98) | 0.203 |
| Death | 2.28 (0.37-13.89) | 0.370 |
| **Immunovirological data** |  |  |
| CD4 nadir  | 0.99 (0.98-0.991) | <0.001 |
| CD4/CD8 ratio at baseline | 0.02 (0.005-0.08) | <0.001 |
| CD8 at 36 months  | 0.99 (0.98-0.99 | <0.001 |
| HIV-RNA zenith (for each log10 copies/mL | 0.94 (0.73-1.20) | 0.623 |
| Months to HIV-RNA ≤ 50 copies/mL  | 0.99 (0.92-1.07) | 0.837 |
| **Therapy**  |  |  |
| Months of INI exposure | 1.01 (1.00-1.03) | 0.051 |
| Months of PI exposure | 1.002 (0.99-1.02) | 0.795 |
| Months of NNRTI exposure | 0.98 (0.97-10.99) | 0.016 |

SD, standard deviation; MSM, men who have sex with men; IVDU intravenous drug users; HBsAg epatitis B surface antigen; IQR, interquartile range.

**Supplementary Table 3. Odds ratio for being INR200 36 months after initiating ART. Only people with CD4 nadir below 200 cells/mmc included in the analysis (N=143).**

|  |  |  |
| --- | --- | --- |
| **Variable**  | **OR (99%CI)** | ***p* value** |
| Age (1 year older)  | 1.06 (0.98-1.13) | 0.113 |
| Male sex | 1.31 (0.14-12.10) | 0.813 |
| Non-Italian nationality | 0.53 (0.05-4.92) | 0.580 |
| Risk factor for HIV (Ref. Heterosexuals) |  |  |
| - MSM  | 2.9e-8 (0-inf) | 0.995 |
| - IVDU  | 1.56 (0.12-16.00) | 0.707 |
| - Unknown  | 2.9e-8 (0-inf) | 0.998 |
| CDC stage C | 0.81 (0.13-5.045) | 0.828 |
| HCV-RNA positivity  | 1.78 (0.19-16.87) | 0.616 |
| HBsAg positivity  | 2.3e-7 (0-inf) | 0.995 |
| CMV IgG positivity | 4.8e+6 (0-inf) | 0.993 |
| Chemotherapy | 2.2e-7 (0-inf) | 0.995 |
| Death | 11.25 (0.95-133.27) | 0.055 |
| **Immunovirological data** |  |  |
| CD4 nadir  | 0.98 (0.95-1.01)) | 0.082 |
| CD4/CD8 ratio at baseline | 0.01 (2.1e-7-51.56) | 0.246 |
| CD8 at 36 months | 0.99 (0.99-1.01) | 0.542 |
| HIV-RNA zenith (for each log10 copies/mL | 0.68 (0.32-1.42) | 0.304 |
| Months to HIV-RNA ≤ 50 copies/mL  | 1.05 (0.83-1.33) | 0.632 |
| **Therapy**  |  |  |
| Months of INI exposure | 1.03 (0.97-1.08) | 0.292 |
| Months of PI exposure | 1.01 (0.95-1.06) | 0.887 |
| Months of NNRTI exposure | 0.99 (0.92-1.06) | 0.736 |

SD, standard deviation; MSM, men who have sex with men; IVDU intravenous drug users; HBsAg epatitis B surface antigen; IQR, interquartile range.